Treatment Options for Pulmonary MAC

Treating Mycobacterium avium complex (MAC) is a long-term commitment that requires a combination of several antibiotics. Because these bacteria are naturally resistant to many common drugs, a single antibiotic is never enough—using only one drug selects for drug-resistant organisms that are much harder to kill, so never start, stop, or use a leftover antibiotic without your clinician’s advice ^[1][2].

The ‘Big Three’ Standard Regimen

For most patients with macrolide-susceptible pulmonary MAC, the foundation of treatment is a three-drug combination often called the “Big Three” ^[1]. Current guidelines recommend this specific backbone ^[1][3]:

1. A Macrolide: Usually Azithromycin (or sometimes Clarithromycin). Azithromycin is often preferred because of tolerability and drug interactions. This is the most important drug in the mix ^[1][4].
2. Ethambutol: A drug that helps break down the bacteria’s tough outer wall ^[1].
3. A Rifamycin: Either Rifampin or Rifabutin ^[1].

Critical Note on Susceptibility: Before you finalize a long-term regimen, your doctor should perform macrolide susceptibility testing on your specific strain of MAC, which provides an MIC (Minimum Inhibitory Concentration)—a laboratory measure of how much drug inhibits growth, interpreted by your specialist ^[5]. If your MAC is already resistant to macrolides, the standard “Big Three” will not work, and you will need specialized treatment for resistant disease managed by an expert ^[2][6]. (However, treatment is sometimes initiated urgently before these results return.)

Tailoring Treatment to Your Disease

Your treatment schedule depends on the “phenotype” (the appearance and severity) of the disease in your lungs ^[1][7].

Note: This table reflects typical options only. Do not change your schedule or add/stop drugs without an NTM specialist.

The 12-Month Rule

The most common question patients ask is, “When can I stop?” In MAC treatment, the clock doesn’t start at your first dose. Instead, guidelines state that you must continue your antibiotics for at least 12 months AFTER your culture conversion ^[1][3].

Culture conversion is generally defined as three consecutive negative cultures collected at least four weeks apart ^[8]. The 12-month period is counted from the date of the first of those three negative cultures. Because it can take several months of treatment just to reach that first negative culture, the total time on antibiotics is often 18 months or longer ^[1][9].

When Initial Treatment Isn’t Enough: Refractory MAC

For some patients, the standard “Big Three” regimen does not clear the bacteria after six months of appropriate, consistent use. This is known as refractory MAC ^[8][9].

If your cultures remain positive after six months, your doctor may consider adding a specialized inhaled medication called ALIS (Amikacin Liposome Inhalation Suspension, brand name Arikayce) ^[8].

• How it works: This is amikacin wrapped in tiny fat bubbles (liposomes) that are inhaled through a specific nebulizer (Lamira), delivering the drug directly to the site of infection in the lungs ^[8][10].
• Effectiveness: In clinical trials, adding ALIS to a standard regimen significantly increased the chances of reaching culture conversion compared to standard drugs alone ^[8][11].
• Monitoring: ALIS can cause side effects like hoarseness (dysphonia), cough, or more rarely, hearing changes, as well as serious risks like bronchospasm, hypersensitivity pneumonitis, and kidney toxicity. Close monitoring by your care team is essential, and you should seek medical advice for new breathing problems or significant bleeding ^[11][12].

Treatment is a marathon, and your doctor will use regular sputum tests to ensure the medications are working and to watch for any signs of the bacteria developing resistance ^[1][13].